Brepocitinib Overview & RVT-3101 Update
2022 Has Been an Incredible Year for Roivant ...
Commercial Launch of VTAMA
Became #1 most prescribed
branded topical for psoriasis 8
weeks into launch
Executed first major PBM/payer
contract
Japanese partner reported positive
topline results in Phase 3 trial in
AD
Demonstrated favorable PK and
safety in pediatric subjects with
AD
Pipeline Composition
RVT-3101 and brepocitinib:
☐ Announced collaborations with
Pfizer
IMVT-1402: Unveiled next-
generation anti-FcRn
Batoclimab: Announced new
indications
Optimized pipeline and extended
runway by discontinuing six
programs
n
Clinical Progress
Brepocitinib: Initiated Phase 3 trial
in DM
Brepocitinib: Completed
enrollment in global Phase 2B trial
in SLE
Namilumab: Initiated Phase 2 trial
in sarcoidosis
RVT-2001: Expanded ongoing
Phase 1/2 trial in lower-risk MDS
Batoclimab: Initiated Phase 3 trials
in MG and TED
Additional Upside
Established multiple partnerships in targeted protein
degradation with aggregate milestone payments over $1B
plus product royalties
roivant
ли
LNP patent litigation progressed in Roivant's favor
For investor audiences only
3View entire presentation